For now, there’s no hard and fast rule when it comes to the slippery slope CBD companies will have to contend with until the FDA starts approving products. Until then, it’s best to err on the side of caution and avoid making any claims you can’t back up with hard science and cited studies, lest draw the ire of government officials who can and will put you out of business if you don’t heed their warnings.
